Diuretics

Frusemide Injection 10 mg per ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Frusemide Tablets 40 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Losartan Potassium and Hydrochlorothiazide combines a selective AT1 receptor blocker with a thiazide diuretic on the WHO Model List of Essential Medicines. Losartan blocks angiotensin II-induced vasoconstriction and uniquely possesses intrinsic uricosuric properties that increase uric acid excretion, offsetting the hyperuricemic tendency of hydrochlorothiazide, while hydrochlorothiazide reduces extracellular fluid volume. Indicated for the treatment of hypertension not adequately controlled on monotherapy and for reducing stroke risk in hypertensive patients with left ventricular hypertrophy.

Telmisartan and Hydrochlorothiazide combines an AT1 angiotensin II receptor antagonist with a thiazide diuretic. Telmisartan suppresses the renin-angiotensin-aldosterone axis, while hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted renal tubules, increasing urinary excretion of sodium, chloride, and water. Telmisartan counteracts diuretic-induced potassium wasting and metabolic disturbances. Indicated for the treatment of hypertension not adequately controlled on telmisartan monotherapy.

Torasemide is a high-ceiling loop diuretic of the pyridine-sulfonylurea class. It inhibits the Na+/K+/2Cl- luminal carrier in the thick ascending limb of Henle's loop, producing potent natriuresis and diuresis. Unlike furosemide, torasemide features high, predictable oral bioavailability (around 80%), a longer duration of action, and antialdosterone properties that decrease myocardial collagen accumulation. Indicated for edema associated with congestive heart failure, chronic renal failure, and hepatic cirrhosis, and for essential hypertension.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Indapamide is an indole-derivative thiazide-like chlorosulfamoyl diuretic and arterial vasodilator on the WHO Model List of Essential Medicines. At antihypertensive doses, it exhibits a dual mechanism: direct vascular action (stimulating prostaglandin PGE2 synthesis and blocking calcium influx in vascular smooth muscle to reduce peripheral resistance) combined with mild distal tubular natriuresis, exerting virtually neutral effects on lipids and glucose. Indicated for essential hypertension, alone or in fixed-dose combination with ACE inhibitors (perindopril) or CCBs.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Torsemide Tablets 20 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Chlorthalidone Tablets 12.5mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Hydrochlorothiazide Tablets 12.5mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Telmisartan and Hydrochlorothiazide combines an AT1 angiotensin II receptor antagonist with a thiazide diuretic. Telmisartan suppresses the renin-angiotensin-aldosterone axis, while hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted renal tubules, increasing urinary excretion of sodium, chloride, and water. Telmisartan counteracts diuretic-induced potassium wasting and metabolic disturbances. Indicated for the treatment of hypertension not adequately controlled on telmisartan monotherapy.

Amiloride 2.5mg + Hydrochlorothiazide 25mg Tablet is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Chlorthalidone Tablets 6.25 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Telmisartan, Amlodipine, and Hydrochlorothiazide is a triple-action fixed-dose antihypertensive combination uniting three complementary hemodynamic mechanisms: an angiotensin II receptor blocker (ARB), a dihydropyridine calcium channel blocker (CCB), and a thiazide diuretic. Telmisartan blocks AT1 receptors and activates PPAR-gamma; amlodipine relaxes peripheral arterial smooth muscle; and hydrochlorothiazide promotes natriuresis, eliminating excess intravascular volume. Indicated for moderate-to-severe essential hypertension in patients not adequately controlled on dual-therapy regimens.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Azilsartan 40mg + Chlorthalidone 6.25mg Tablet is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Azilsartan Medoxomil 40mg + Chlorthalidone 12.5mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Eplerenone Tablets 25 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Telmisartan and Amlodipine is a synergistic dual antihypertensive formulation. Telmisartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at AT1 receptors and improves insulin sensitivity via partial PPAR-gamma agonism, while amlodipine selectively inhibits transmembrane calcium influx in vascular smooth muscle, producing peripheral arteriolar vasodilation. Telmisartan post-capillary venodilation mitigates amlodipine-induced pre-capillary peripheral ankle edema. Indicated for essential hypertension in patients whose blood pressure is not adequately controlled on monotherapy.

Telmisartan and Amlodipine is a synergistic dual antihypertensive formulation. Telmisartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at AT1 receptors and improves insulin sensitivity via partial PPAR-gamma agonism, while amlodipine selectively inhibits transmembrane calcium influx in vascular smooth muscle, producing peripheral arteriolar vasodilation. Telmisartan post-capillary venodilation mitigates amlodipine-induced pre-capillary peripheral ankle edema. Indicated for essential hypertension in patients whose blood pressure is not adequately controlled on monotherapy.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Tolvaptan Tablets 15mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Torasemide and Spironolactone is a balanced dual-action diuretic formulation. Torasemide is a high-potency pyridine-sulfonylurea loop diuretic that inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, while spironolactone is a competitive aldosterone receptor antagonist in the distal convoluted tubule and collecting duct. Spironolactone prevents loop diuretic-induced potassium wasting and secondary hyperaldosteronism, reducing cardiac fibrosis while promoting sustained natriuresis. Indicated for resistant edema associated with congestive heart failure, hepatic cirrhosis with ascites, and nephrotic syndrome.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Torsemide Tablets 100mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Combikit of Eplerenone Tablets 25mg + Torsemide Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Metolazone is a quinazoline-derivative thiazide-like diuretic. It inhibits sodium reabsorption at the cortical diluting segment of the distal renal tubule and proximal tubule. Uniquely, it retains its diuretic potency even in advanced renal failure (GFR < 20 mL/min) where standard thiazides fail, and exhibits profound synergistic diuresis ("sequential nephron blockade") when combined with loop diuretics. Indicated for severe refractory edema accompanying congestive heart failure and renal disease, and hypertension.

Telmisartan, Amlodipine, and Hydrochlorothiazide is a triple-action fixed-dose antihypertensive combination uniting three complementary hemodynamic mechanisms: an angiotensin II receptor blocker (ARB), a dihydropyridine calcium channel blocker (CCB), and a thiazide diuretic. Telmisartan blocks AT1 receptors and activates PPAR-gamma; amlodipine relaxes peripheral arterial smooth muscle; and hydrochlorothiazide promotes natriuresis, eliminating excess intravascular volume. Indicated for moderate-to-severe essential hypertension in patients not adequately controlled on dual-therapy regimens.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Losartan Potassium and Hydrochlorothiazide combines a selective AT1 receptor blocker with a thiazide diuretic on the WHO Model List of Essential Medicines. Losartan blocks angiotensin II-induced vasoconstriction and uniquely possesses intrinsic uricosuric properties that increase uric acid excretion, offsetting the hyperuricemic tendency of hydrochlorothiazide, while hydrochlorothiazide reduces extracellular fluid volume. Indicated for the treatment of hypertension not adequately controlled on monotherapy and for reducing stroke risk in hypertensive patients with left ventricular hypertrophy.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Eplerenone 50mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Hydrochlorothiazide Tablets 25 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Losartan Potassium is the prototype selective competitive angiotensin II receptor type 1 (AT1) antagonist on the WHO Model List of Essential Medicines. It blocks the physiological actions of angiotensin II, lowering systemic vascular resistance and aldosterone secretion, while its active metabolite EXP3174 provides long-acting non-competitive blockade. Possesses unique uricosuric activity, lowering serum uric acid levels. Indicated for essential hypertension, diabetic nephropathy in type 2 diabetes with elevated creatinine and proteinuria, and stroke reduction in hypertensive patients with left ventricular hypertrophy.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.